 |
Medication Safety Officers Society 3680 Members Strong A society of healthcare professionals dedicated to improving medication safety in healthcare organizations |
PLEASE NOTE: Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP).
Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org.
Curious how pump programming is being built for this combination product. For the bamlanivimab 700 mg, etesevimab 1400 mg are you:
-listing the mg for 1 of the agents and having a clinical alert indicating it is a combination product with both mg strengths?
-listing the total mg (i.e. 2100 mg) with a clinical alert indicating individual monoclonal antibody strengths?
-Other alternate build (please elaborate)
Thank you so much for any insight into your practices you can provide.